Skip to main content

Table 3 Evolution of treatment recommendations

From: Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Risk category

Low-risk group (N = 154)

Non-low-risk group (N = 67)

Recommendation, n

CT + HT

HT

CT + HT

HT

1st tumor board

41 (27%)

113 (73%)

48 (72%)

19 (28%)

1st shared decision

40 (26%)

114 (74%)

47 (70%)

20 (30%)

 

Add knowledge of recurrence score

2nd tumor board

28 (18%)

126 (82%)

32 (48%)

35 (52%)

2nd shared decision

24 (16%)

130 (84%)

32 (48%)

35 (52%)

Treatment actually given

23 (15%)

130 (84%)

28 (42%)

37 (55%)

  1. CT chemotherapy, HT endocrine therapy